The utilization of cytokines in stem cell mobilization strategies

Bone Marrow Transplantation

Volumn 23, Issue , 1999, Pages S13-S19

  Shpall, Elizabeth J ^a  

^a UNIVERSITY OF COLORADO HOSPITAL   (United States)

Author keywords

Cytokines; High dose chemotherapy; Stem cells

Indexed keywords

CARMUSTINE; CD34 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOKINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEM CELL FACTOR;

ADVERSE DRUG REACTION; APHERESIS; BREAST CANCER; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; INJECTION SITE; MULTICENTER STUDY; PERIPHERAL BLOOD STEM CELL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD CELL COUNT; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III; CYTOKINES; FEMALE; FILGRASTIM; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; RANDOMIZED CONTROLLED TRIALS; TRANSPLANTATION, AUTOLOGOUS;

EID: 0032934165     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701669     Document Type: Article

References (37)

1. Sheridan WP, Begley CG, Juttner CA et al. Effect of peripheral- blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640–644.
2. Schmitz N, Linch DC, Dreger P et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353–357.
3. Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheralblood stem cells. J Clin Oncol 1995; 13: 2547–2555.
4. Glaspy JA, Shpall EJ, LeMaistre CF et al. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood 1997; 90: 2939–2951.
5. Tricot G, Jagannath S, Vesole DH et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588–596.
6. Weaver CH, Hazelton B, Birch R et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961–3969.
7. Kiss JE, Rybka WB, Winkelstein A et al. Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1997; 19: 303–310.
8. Dercksen MW, Rodenhuis S, Dirkson MKA et al. Subsets of CD34+ cells and rapid hematopoietic recovery after peripheral- blood stem-cell transplantation. J Clin Oncol 1995; 13: 1922–1932.
9. Moskowitz CH, Stiff P, Gordon MS et al. Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non- Hodgkin’s lymphoma patients—results of a phase I/II trial. Blood 1997; 89: 3136–3147.
10. Weaver A, Ryder D, Crowther D et al. Increased numbers of long-term culture-initiating cells in the apheresis product of patients randomized to receive increasing doses of stem-cell factor administered in combination with chemotherapy and a standard dose of granulocyte colony-stimulating factor. Blood 1996; 88: 3323–3328.
11. Begley CG, Basser R, Mansfield R et al. Enhanced levels and enhanced clonogenic capacity of blood progenitor cells following administration of stem cell factor plus granulocyte colony- stimulating factor to humans. Blood 1997; 90: 3378–3389.
12. Rasko JEJ, Basser RL, Boyd J et al. Multilineage mobilization of peripheral blood progenitor cells in humans following administration of PEG-rHuMGDF. Br J Haematol 1997; 97: 871–880.
13. Basser RL, Rasko JEJ, Clarke K et al. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood 1997; 89: 3118–3128.
14. Lebsack ME, McKenna HJ, Hoek JA et al. Safety of FLT3 ligand in healthy volunteers. Blood 1997; 90 (suppl 1): 170a.
15. DiPersio JF, Abboud CN, Schuster MW et al. Phase II study of mobilization of PBSC by administration of daniplestim (SC-55494) and G-CSF in patients with breast cancer lymphoma. Proc ASCO 1997; 16: 87a (Abstr.).
16. Galli SJ, Zsebo KM, Geissler EN. The kit ligand, stem cell factor. Adv Immuno 1994; 55: 1–95.
17. Morstyn G, Brown S, Morstyn G et al. Stem cell factor is a potent synergistic factor in hematopoiesis. Oncology 1994; 51: 205–214.
18. McNiece IK, Briddell RA, Hartley CA et al. Stem cell factor enhances in vivo effects of granulocyte colony stimulating factor for stimulating mobilization of peripheral blood progenitor cells that have enhanced repopulating potential. Stem Cells 1993; 11 (Suppl. 2): 36–41.
19. Broudy VC. Stem cell factor and hematopoiesis. Blood 1997; 90: 1345–1364.
20. Demetri G. A Phase 1 trial of recombinant methionyl human stem cell factor (SCF) in patients with advanced breast carcinoma pre- and postchemotherapy (CHEMO) with cyclophosphamide (C) and doxorubicin (A). Proc Am Soc Clin Oncol 1993; 12: 142.
21. Bezwoda WR, Seymour L, Dansey RD et al. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995; 13: 2483–2489.
22. Hurd DD, Peters WP. Randomized, comparative study of high-dose (with autologous bone marrow support) versus lowdose cyclophosphamide, cisplatin, and carmustine as consolidation to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for patients with operable stage II or III breast cancer involving 10 or more axillary lymph nodes (CALGB Protocol 9082). Cancer and Leukemia Group B. J Natl Cancer Inst Monogr 1995; 19: 41–44.
23. Bitran JD, Samuels B, Klein L et al. Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer. Bone Marrow Transplant 1996; 17: 157–162.
24. Siena S, Bregni M, Brando B et al. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 1991; 77: 400–409.
25. Laport GF, Zimmerman TM, Grinblatt GC et al. CD34+ peripheral blood stem cell (PBSC) dose influences engraftment kinetics and other relevant clinical variables. Proc ASCO 1996; Abstr. 956.
26. Boroson R, Brown R, Hendricks D et al. Hematopoietic recovery after stem cell transplantation: impact of CD34+ cell dose and method of mobilization. Blood 1991; 84: 349a (Abstr. 1381).
27. Schiller G, Vescio R, Freytes C et al. Transplantation of CD34+ peripheral blood progenitor cells after high dose chemotherapy for patients with advanced multiple myeloma. Blood 1995; 86: 390–397.
28. Zimmerman TM, Lee WJ, Bener JG et al. Quantitative CD34 analysis may be used to guide peripheral blood stem cell harvests. Bone Marrow Transplant 1995; 9: 439–444.
29. Haas R, Mohle R, Fruhauf S et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787–3794.
30. Haynes A, Hunter A, McQuaker G et al. Engraftment characteristics of peripheral blood stem cells mobilised with cyclophosphamide and the delayed addition of G-CSF. Bone Marrow Transplant 1995; 16: 359–363.
31. Papadopoulos KP, Ayello J, Tugulea S et al. Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast cancer scheduled for high-dose chemotherapy and peripheral blood progenitor cell support. J Hematol 1997; 6: 61–68.
32. Schwella N, Beyer J, Schwaner I et al. Impact of preleukapheresis cell counts on collection results and correlation of progenitor- cell dose with engraftment after high-dose chemotherapy in patients with germ cell cancer. J Clin Oncol 1996; 14: 1114–1121.
33. Sola C, Maroto P, Salazar R et al. High dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) autologous transplantation: Influence of the number of infused CD34+ cells in hematopoietic recovery and support measures required. Proc ASCO 1996; 15: 538 (Abstr. 1746).
34. van der Wall E, Richel DJ, Holtkamp MJ et al. Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: effect of graft size. Ann Oncol 1994; 5: 795–802.
35. Weaver CH, Birch R, Schulman KA. Effect of cell dose on resource utilization in patients undergoing transplant with peripheral blood progenitor cells. Blood 1997; 90 (Suppl. 1): 370a (Abstr. 1647).
36. Goldberg SL, Mangan KF, Klumpp JS et al. Complications of peripheral blood stem cell harvesting: review of 554 PBSC leukaphereses. J Hematother 1995; 4: 85–90.
37. Shpall EJ, Wheeler CA, Turner SA et al. A randomized phase study of PBPC mobilization by stem cell factor and filgrastim in patients with high-risk breast cancer. Blood 1999. (in press).